Human/Mouse CXCL12/SDF-1 Antibody Best Seller

CXCL12/SDF-1 in Human Tonsil.

CXCL12/SDF-1 was detected in immersion fixed paraffin-embedded sections of human tonsil using Human/Mouse CXCL12/SDF-1 Monoclonal Antibody (Catalog # MAB350) at 25 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

Detection of CXCL12/SDF-1 in HT1080 Human Cell Line by Flow Cytometry.

HT1080 human fibrosarcoma cell line was stained with Mouse Anti-Human/Mouse CXCL12/SDF-1 Monoclonal Antibody (Catalog # MAB350, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0102B). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012). View our protocol for Staining Intracellular Molecules.

CXCL12/SDF‑1 alpha in Human Tonsil Using Dual RNAscope^®ISH and IHC.

CXCL12/SDF-1a mRNA was detected in formalin-fixed paraffin-embedded tissue sections of human tonsil probed with ACD RNAScope^®Probe (Catalog # 422991) and stained using ACD RNAscope^®2.5 HD Detection Reagents-Red (top image, Catalog # 32260). Adjacent tissue section was processed for immunohistochemistry using R&D Systems Mouse Anti-Human CXCL12/SDF-1a Monoclonal Antibody (Catalog # MAB350) at 5 ug/mL for 1 hour at room temperature followed by incubation with the Anti-Mouse IgG VisUCyte HRP Polymer Antibody (R&D Systems, Catalog # VC001) and DAB chromogen (lower image, yellow-brown). Tissues were counterstained with hematoxylin (blue).

Detection of Human CXCL12/SDF-1 by Immunocytochemistry/Immunofluorescence

CXCR4 and CXCL12 expression and BM infiltration. (a) Expression analysis of CXCR4 and CXCL12 in uninfiltrated and infiltrated bone marrow specimens at the time of diagnosis by RQ-PCR. (b) Expression analysis of CXCR4 and CXCL12 in infiltrated bone marrow biopsies and the respective paired sample in patients under remission by RQ-PCR. (c) Representative immunohistochemical stains of CXCR4 (I–II) and CXCL12 (III–IV) on selected bone marrow specimens of DLBCL patients (magnification 20×). (I) and (III) represent the CXCR4 and CXCL12 staining of uninfiltrated bone marrow specimens, and (II) and (IV) represent those of the infiltrated bone marrow specimens. mRNA expression levels were calculated as a relative expression in comparison to uninfiltrated bone marrow specimens. Each bar represents the mean values of expression levels ± standard error of the mean (SEM). The comparison of the expression levels was performed by using the Mann–Whitney U-test or the Student’s t-test. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31554271), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse CXCL12/SDF-1 by Immunohistochemistry

RhoA modulates the CXCR4-CXCL12 axis in breast tumors. (a) Representative immunohistochemical (IHC) staining images of breast primary tumor sections of mice orthotopically injected with 4T1 GFP-LUC cells carrying indicated lentiviral modifications, stained with antibodies for CD31 (top, left), F4/80 (middle, left) and alpha-SMA (bottom, left). CD31+ area (top, right), F4/80+ cells (middle, right) and alpha-SMA+ area (bottom, right) per tumor field of view (FOV) (mean ± SE) quantifications of IHC images. N = 4. (b) Representative IHC staining images of breast primary tumor sections of above mice stained with CXCL12 antibody (left). CXCL12+ area per tumor FOV (mean ± SE) quantification of IHC images. N = 4. (c) Representative immunofluorescent images of breast primary tumor sections of above mice co-stained with alpha-SMA, CXCL12 and DRAQ5 nuclear stain, showing the co-localization of alpha-SMA and CXCL12 signals. Scale bar: 50 µm. (d) Representative IHC staining images of breast primary tumor sections of above mice stained with CXCR4 antibody (left). CXCR4+ area per tumor FOV (mean ± SE) quantification of IHC images. N = 4. (e) Relative mCXCR4 mRNA levels normalized with mActin (mean ± SE), as quantified by qRT-PCR in primary breast tumors of above mice (top) and in 4T1 GFP-LUC cells carrying indicated lentiviral modifications (bottom). N = 4, ns- not significant *P < 0.05, unpaired Student’s t-test (two-tailed). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31705019), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human CXCL12/SDF-1 by Immunocytochemistry/Immunofluorescence

CXCR4 and CXCL12 expression in DLBCL. (a) Expression analysis of CXCR4 and CXCL12 in non-neoplastic control germinal center B cells (GC-B) and diffuse large B cell lymphoma cells (DLBCL) consisting of DLBCL-NGCB and DLCBL-GCB, by RQ-PCR. GCB-DLBCL were further subdivided into primary (DLBCL-pGCB) and transformed DLBCL (DLBCL-pGCB) originating from follicular lymphoma. (b) Expression analysis of CXCR4 and CXCL12 in DLBCL samples with early (stage 1) and advanced stage (stage 2–4) (left graphs) and DLBCL samples with and without bone marrow infiltration (right graphs) by RQ-PCR. (c) Probability of 5-year-survival in DLBCL patients (our cohort left panel and the cohort of Lenz et al. right [20]) stratified by the third quartile of CXCR4 expression, respectively. (d) Representative immunohistochemical stains of CXCR4 (I–III) and CXCL12 (IV–VI) on DLBCL samples (magnification 20×). mRNA expression levels were calculated as a relative expression in comparison to the GC-B cells. All images were captured using an Olympus BX51 microscope and an Olympus E-330 camera. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31554271), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Human Human/Mouse CXCL12/SDF-1 Antibody by Immunohistochemistry

Tumor-promoting phenotype of the myeloid clusters.IHC staining demonstrating the expression of CD163, IL-6, IL-10, VEGF-A, MMP-9, SDF-1 and Bcl-xL by the myeloid cells associated with anthracosis. For each protein, representative images showing positive and negative staining areas were selected from the same slide. The quantification was performed by analyzing random images of myeloid cluster areas associated with anthracosis and other areas (10 images for each group) from 10 patients. Two-tailed Student's t-test was used for statistical analysis. Shown are means ± SEM, *** P<0.001. (Scale bar, 200 µm for 100× and 400×; 25 µm for 1600×) Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/23717691), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Mouse CXCL12/SDF-1 by Immunohistochemistry

Afferent lymph vessels in chronically inflamed skin express CXCL12.Immunofluorescence staining of frozen sections of chronically inflamed skin (21 days after inflammation elicited by subcutaneous injection of CFA) for CXC12 and CCL21 by LYVE-1+ lymph vessels using DAPI counterstaining. One representative image of lymph vessels analyzed in 5 mice is shown. Scale bars, 10 µm. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/24752354), licensed under a CC-BY license. Not internally tested by R&D Systems.